Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

June 7, 2012

Date of Report (date of earliest event reported)

 

 

SOLTA MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-33123   68-0373593

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification Number)

25881 Industrial Boulevard, Hayward, California 94545

(Address of principal executive offices)

(510) 782-2286

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

Solta Medical, Inc. (the “Company”) held its 2012 Annual Meeting of Stockholders (“Annual Meeting”) on June 7, 2012, to vote on the following proposals:

 

  1. Election of three Class III directors, Cathy L. McCarthy, Mark M. Sieczkarek and Eric Stang, to serve a three year term which will expire at the 2015 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified. All directors were elected in accordance with the votes below:

 

Nominees

   Shares For      Shares Withheld      Broker Non-Votes  

Cathy L. McCarthy

     35,853,224         3,329,280         14,099,971   

Mark M. Sieczkarek

     35,825,454         3,357,050         14,099,971   

Eric Stang

     35,008,918         4,173,586         14,099,971   

 

  2. Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2012. Deloitte & Touche LLP was ratified as our independent registered public accounting firm for the fiscal year ending December 31, 2012 in accordance with the votes below:

 

Shares For

 

Shares Against

 

Shares Abstaining

 

Broker Non-Votes

53,070,577

  114,520   97,378   0

 

  3. Advisory Vote on executive compensation. The shareholders voted to approve the compensation of our named officers in accordance with the votes below:

 

Shares For

 

Shares Against

 

Shares Abstaining

 

Broker Non-Votes

37,140,036

  529,492   1,512,976   14,099,971

 

  4. Amendment of our Amended and Restated Certificate of Incorporation to eliminate the supermajority voting threshold. The Amendment of our Amended and Restated Certificate of Incorporation required a vote of 66-2/3% of the outstanding stock. It was not approved in accordance with the votes below:

 

Shares For

 

Shares Against

 

Shares Abstaining

 

Broker Non-Votes

37,583,260

  199,872   1,399,372   14,099,971


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SOLTA MEDICAL, INC.
Date: June 8, 2012     By:  

/s/ John F. Glenn

      John F. Glenn
      Chief Financial Officer